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ReviewReaching a Genetic and Molecular
Understanding of Skeletal Development
patterning were not really involved in the control of cell
differentiation.
Thus, the development of the skeleton encompasses
Gerard Karsenty1,3 and Erwin F. Wagner2
1Department of Molecular and Human Genetics
Baylor College of Medicine
Houston, Texas 77030 two fairly distinct areas: on the one hand, the analysis of
the genetic and molecular control of skeletal patterning2 IMP—Research Institute of Molecular Pathology
A-1030 Vienna and, on the other hand, the study of the genetic and
molecular control of cell differentiation in the chondro-Austria
cyte, osteoblast, and osteoclast lineages. The ever-
increasing breadth and complexity of each of these as-
pects makes it virtually impossible to address them both
In the last ten years, we have made considerable prog- in a single review of limited length. We have decided to
ress in our genetic and molecular understanding of focus this review on the process of cell differentiation,
all aspects of skeletal development, chondrogenesis, mainly because this is the area in which much progress
joint formation, and osteogenesis. This review ad- has been made recently.
dresses the role of the principal growth factors and When development is complete, most of the skeleton
transcription factors affecting these different pro- is made of bone, whose formation can be viewed as
cesses and presents, in several cases, the genetic a major endpoint of skeletal development. There are,
cascade leading to cell differentiation. however, two ways to get to this endpoint. In both cases
mesenchymal cells first have to aggregate to form mes-
Introducing the Cast of Characters enchymal condensations that prefigure the shape of,
At the beginning of the writing process of an extensive and are situated at the location of, future skeletal ele-
review, one has to ask, is there is a real need for this, ments. Beyond this patterning event, in most cases,
and, if yes, why? For skeletal development the answer the cells of the mesenchymal condensations will then
is a resounding yes, because major progress has been differentiate into chondrocytes that form the template,
made in the last three years and a fortiori in the last or anlagen, of the future bone. Later on, through a pro-
seven years (Karsenty, 1999; Erlebacher and Derynck, cess called endochondral ossification, which is detailed
1996). There is now a much a better understanding of below, this cartilaginous template will eventually be re-
the transcriptional control of chondrocyte differentiation placed by bone. In the other cases cells of the mesen-
and an improved knowledge of joint formation. Genes chymal condensations will bypass the cartilaginous in-
upstream and downstream of Cbfa1 in osteoblast differ- termediary step and will differentiate directly into
entiation have been identified, a novel Cbfa1-indepen- osteoblasts. This process, called intramembranous os-
dent pathway to control osteoblast proliferation has sification, occurs in a few skeletal elements, such as
been discovered, and there is a continuing refinement the lateral halves of the clavicles and parts of the skull
in our knowledge of osteoclast differentiation. The im- (Hall, 1988).
portance of these new developments fully justifies the
writing of this review.
The Beginning: Chondrogenesis, Its GeneticTwo features characterize skeletal biology. The first
and Molecular Controlfeature is that, unlike most organs, e.g., liver, heart, and
Chondrocytes in cartilage play several pivotal roles inbrain, the skeleton is not confined to one structure or
the formation of most of the vertebrate skeleton. Besidesone location in the body but rather is made of more
their role during osteogenesis, chondrocytes in thethan 200 elements that are spread throughout the body.
growth plate control longitudinal growth of the skeleton.Moreover, all these elements have unique shapes. Thus,
Finally, they control skeleton mobility by their presencea critical component of skeletal development has been,
in and around joints. Thus, chondrogenesis is both theand will remain to be in the foreseeable future, to identify
earliest step of skeletogenesis and one that affects mul-the genes and genetic pathways that control skeletal
tiple aspects of this developmental process.patterning, i.e., the definition of the shape and location
In the center of the condensations that will give rise toof a particular skeletal element. The second characteris-
bone through endochondral ossification, mesenchymaltic of the skeleton is that it is an organ made of two
cells differentiate first into chondrocytes that expressdistinct tissues, cartilage and bone. There are in each
specific molecular markers, such as aggrecan and 1(II)of these tissues specific cell types: the chondrocyte in
collagen. The expression of these molecular markerscartilage and the osteoblast and osteoclast in bone.
distinguishes differentiating chondrocytes from the un-Two of these cell types, chondrocytes and osteoblasts,
differentiated mesenchymal cells remaining at the pe-are of mesenchymal origin and share a common progen-
riphery of the skeletal element that form a structureitor (Ducy et al., 1997), whereas osteoclasts derive from
called the perichondrium (Horton, 1993). Once the carti-the myelomonocytic lineage. One of the major surprises
laginous templates are formed, the innermost chondro-from the early days of mouse genetics—nowadays for-
cytes further differentiate into hypertrophic chondro-gotten—was to realize that genes controlling skeleton
cytes. These cells are, by many criteria, different from
the nonhypertrophic chondrocytes and can themselves
be subdivided into two populations: the prehypertrophic3 Correspondence: karsenty@bcm.tmc.edu
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Figure 1. Schematic Representation of the
Late Steps of Endochondral Ossification
The region of cartilage-containing hypertro-
phic chondrocytes is surrounded by the bone
collar and other mesenchymal cells. Hyper-
trophic chondrocyte differentiation is favored
by Cbfa1 and Ihh and inhibited by PTHrP.
Cbfa1 induces Vegf expression, while Ihh in-
duces Cbfa1 expression in the bone collar.
VEGF will be needed for vascular invasion,
bringing in chondroclasts that will remove the
cartilage matrix and osteoblasts that will initi-
ate osteogenesis.
chondrocytes, which still express 1(II) collagen, albeit area, explains why chondrogenesis has been so heavily
studied in recent years. Chondrocytes in the growthat a lower level, and the hypertrophic chondrocytes
proper, which do not express 1(II) collagen but instead plate will regulate longitudinal growth of the skeleton
until their disappearance at the end of puberty in hu-express 1(X) collagen, the only known hypertrophic
chondrocyte-specific molecular marker (Linsenmayer et mans. This constitutes the second important function
of chondrocytes.al., 1991; Poole, 1991). At the time chondrocyte hyper-
trophy is first initiated, i.e., around day 13 (E13) of mouse Chondrocytes are involved in a third important aspect
of skeletogenesis, the development of articulations (Mi-embryonic development, perichondrial cells start to dif-
ferentiate into osteoblasts expressing Cbfa1 to form, trovic, 1977). This process begins at the site of a future
articulation (or joint) with the appearance of regions ofaround the cartilaginous core, a mineralized structure,
termed the bone collar (Caplan and Pechak, 1987), higher cell density called interzones (Figure 3). Cells in
these interzones lose characteristics of a typical chon-whose paramount importance has been uncovered in
recent years (St-Jacques et al., 1999) (Figure 1). drocyte phenotype, such as 1(II) collagen and ag-
grecan expression, and instead express 1(III) collagenOnce fully differentiated, hypertrophic chondrocytes
become surrounded by a calcified extracellular matrix (Craig et al., 1987). The interzone is classically subdi-
vided into three layers. The central layer, a lower-cell(ECM) before they die through apoptosis. This mineral-
ized ECM favors, through a vascular endothelial growth density area, is called the central intermediate lamina.
Cells in this central intermediate lamina will eventuallyfactor (VEGF)-dependent pathway, vascular invasions
from the bone collar, a process that serves two pur- die through apoptosis, thereby creating the joint cavity.
On either side of the central intermediate lamina, thereposes. First, it brings in chondroclasts that will degrade
the ECM surrounding the hypertrophic chondrocytes are two areas of higher cell density. Cells in these two
layers will differentiate into two regions of articular chon-(Vu et al., 1998). Second, it will also bring in progenitors
of osteoblasts derived from the bone collar. The cartilag- drocytes, separated from each other by the joint cavity
(Mitrovic, 1977).inous ECM, rich in type X collagen, will thus be replaced
by a bone ECM, rich in type I collagen. This scaffolding The generic name “chondrocyte” suggests a single
cell population resulting from a single differentiation pro-process allowing osteogenesis to occur is the first im-
portant function of the cartilage template (Figure 1). cess. Reality is different. Indeed, the distinct morphol-
ogy of each chondrocyte subpopulation, the profile ofThe ossification process will then move on centrifu-
gally, consuming much of the cartilage template. As this gene expression in each of these subpopulations, the
temporal sequence of their differentiation, and the spe-hypertrophic cartilaginous front approaches the ends of
a future bone, chondrocytes immediately distal to the cific functions of each of these subpopulations all rather
suggest that the unifying word chondrocyte is some-front proliferate before they hypertrophy. Subsequently,
this sequential process of chondrocyte proliferation, hy- times misleading. We propose here that distinguishing
these cell subpopulations into nonhypertrophic, hyper-pertrophy, and replacement by osteoblasts becomes
organized into the growth plate, an avascular structure trophic, and articular chondrocytes is a more accurate
reflection of biological reality. For the sake of clarity,occupying a narrow space at each end of the expanding
bone (Figure 2). Within the growth plate the various sub- this classification will be used in this review. We will, on
purpose, leave aside another subpopulation of chondro-populations of chondrocytes, resting, proliferating, pre-
hypertrophic, and hypertrophic, are arranged in col- cytes present in permanent cartilaginous structures: the
chondrocostal cartilages, the cartilage of the ear andumns. Such arrangement, representing in a snapshot
the entire sequence of cell differentiation in a confined the intervetebral discs. Little is known about the genetic
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Figure 2. Schematic Representation of the
Growth Plate Columns of Chondrocytes In-
cluding, from Top to Bottom, Resting and
Proliferating (Nonhypertrophic) Chondro-
cytes and Hypertrophic Chondrocytes
On the left side the transcription factors are
depicted in red, and growth factors are de-
picted in blue, regulating the initial differentia-
tion, proliferation, and terminal differentiation
of chondrocytes.
characteristics of these cells, which are presently con- signaling pathway that, in the case of ACH, is overexub-
erant in the presence of ligand. This results in impairedsidered to be very similar to nonhypertrophic chondro-
cytes. cell proliferation and dwarfism. In contrast, Fgfr3 inacti-
vation in mice causes prolonged endochondral boneNonhypertrophic Chondrocyte Differentiation
Nonhypertrophic chondrocytes include reserve and pro- formation, resulting in longer bones. This prolonged
growth is accompanied by an extension of the zone ofliferating chondrocytes. They are considered the carti-
lage-forming cells, since they express 1(II) collagen proliferating chondrocytes within the growth plate (Deng
et al., 1996). Taken together, these human and mouseand aggrecan, the major constituents of the cartilagi-
nous ECM (Horton, 1993), and play a critical role in genetic data demonstrate that FGFR3 is a negative regu-
lator of chondrocyte proliferation. FGFRs are classicallycontrolling the rate of hypertrophic chondrocyte differ-
entiation. viewed as transmitting mitogenic signals; thus, the inhi-
bition of chondrocyte proliferation exerted by FGFR3Several growth factors have been demonstrated to
control nonhypertrophic chondrocyte differentiation in was surprising and could be either a unique property of
FGFR3 or a peculiarity of the FGFR transduction cas-vivo. This field began to blossom when activating muta-
tions in the fibroblast growth factor receptor 3 gene cade in proliferating chondrocytes. That an activating
mutation in FGF receptor 1 (FGFR1) introduced in chon-(Fgfr3) were demonstrated to cause achondroplasia
(ACH), a human condition characterized by a virtual ab- drocytes normally expressing Fgfr3 results in an ACH
phenotype suggests that inhibition of proliferation bysence of nonhypertrophic chondrocytes, and a similar,
more severe, disease called thanatophoric dysplasia FGFR signaling is a property unique to chondrocytes
(Wang et al., 2001).(TD) (Naski et al., 1996; Rousseau et al., 1994; Shiang
et al., 1994; Tavormina et al., 1995). FGFR3, one of the Two of the important questions raised by these obser-
vations are as follows. (1) What is(are) the transcriptionalfour tyrosine-kinase transmembrane proteins serving as
receptors for FGFs, is expressed in proliferating chon- effector(s) located downstream of FGFR3 in chondro-
cytes? (2) Which FGF is the specific ligand of FGFR3 indrocytes. In vitro, ACH and one of the TD mutations
of FGFR3 lead to ligand-independent receptor tyrosine cartilage? Several studies have provided evidence that
the transcription factor STAT1 is a mediator of FGFR3phosphorylation and constitutive activation of the FGF
Figure 3. Joint Development
Within developing skeletal elements the loca-
tion of a future joint is defined by a zone of
higher cell density called the interzone (step
1). Shortly thereafter three layers can be iden-
tified in the interzone; the central layer, called
central intermediate lamina (CIL), has a lower
cell density. On either side of the CIL there are
high-cell density layers (step 2). In the last step
cells within the CIL die through apoptosis,
leaving the joint cavity. Cells in the high-cell
density layers will differentiate into articular
chondrocytes (step 3). The zones of expres-
sion of Wnt14 and GDF5 are indicated.
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action on chondrocyte proliferation. Indeed, activating Suda et al., 1998). In vitro, CNP favors chondrocyte
proliferation and longitudinal growth of fetal bone. Howmutations of FGFR3 induces phosphorylation, activa-
tion, and nuclear localization of STAT1, which, in turn, this pathway relates to the FGF or Ihh pathways has not
yet been elucidated.increases the expression of the cell cycle inhibitor p21.
Moreover, in metatarsal bone cultures, FGF1 treatment Several transcription factors also control differentia-
tion of nonhypertrophic chondrocytes. Human geneticinhibits chondrocyte proliferation in wild-type, but not
in STAT1-deficient, specimens (Sahni et al., 1999; Su et data, expression pattern analyses, and transactivation
studies in vitro and in vivo have all strongly suggestedal., 1997). The role of STAT1 does not exclude that other
transcription factors yet to be defined may be involved that Sox9, a high-mobility group (HMG) box-containing
DNA binding protein plays a major role during nonhyper-in this pathway. There is another question. What is(are)
the ligand(s) binding to FGFR3 that control chondrocyte trophic chondrocyte differentiation (Bell et al., 1997;
Foster et al., 1994; Ng et al., 1997; Wagner et al., 1994).proliferation? This is not an easy question to solve for
at least two reasons: there are 22 FGF proteins (Ornitz The formal demonstration that Sox9 plays a critical role
during chondrogenesis came from an elegant mouseand Itoh, 2001), and deletion of these genes may result
in embryonic lethality before chondrogenesis is initiated. embryo chimera experiment (Bi et al., 1999). In this ex-
periment both copies of Sox9 were inactivated in embry-However, recent studies from D. Ornitz’s laboratory and
others show that FGF18-deficient mice present an ex- onic stem (ES) cells expressing LacZ. The presence of
LacZ allowed one to follow the fate of the Sox9/ cells.panded zone of proliferating chondrocytes similar to
that seen in FGFR3-deficient mice (Liu et al., 2002; Oh- These mutant ES cells were injected into blastocysts
from wild-type females to generate chimeras. Analysisbayashi et al., 2002). This observation suggests that
FGF18 might be the preferred ligand of FGFR3 in regulat- of these chimeras demonstrated that Sox9/ cells were
able to contribute to multiple cell lineages but alwaysing chondrocyte proliferation.
Indian hedgehog (Ihh), a mammalian homolog of the failed to differentiate into chondrocytes and instead re-
mained at the periphery of the skeletal condensations.Drosophila Hedgehog (Hh) secreted factor, regulates
several aspects of skeletogenesis, including nonhyper- This block in differentiation occurred at the mesenchy-
mal condensation stage, identifying Sox9 as the earliesttrophic chondrocyte proliferation. One characteristic of
Ihh-deficient mice is a marked decrease in nonhypertro- determinant of chondrogenesis. Cell culture experi-
ments have shown that Sox9 expression increases uponphic chondrocyte proliferation (St-Jacques et al., 1999).
Part of the mechanism whereby Ihh regulates nonhyper- FGF signaling via a mitogen-activated protein kinase
pathway, thus tying together two critical pathways dur-trophic chondrocyte proliferation was recently eluci-
dated through a series of elegant genetic experiments. ing chondrogenesis (Murakami et al., 2000).
Two other genes encoding the HMG box proteinsHh signaling is transduced through smoothened (Smo),
a G protein-coupled transmembrane protein. In Ihh ab- Sox5 and Sox6 are coexpressed with Sox9 in nonhyper-
trophic chondrocytes. However, unlike Sox9, Sox5 andsence, Smo is repressed by patched-1 (Ptc1), another
cell surface receptor that binds Ihh. Binding of Ihh to Sox6 do not have transactivation domains or detectable
transactivation functions by any in vitro assay. Sox5,Ptc1 relieves the repression of Smo and allows Ihh signal
transduction to take place (Ingham and McMahon, 2001). Sox6, and Sox9 bind to the chondrocyte-specific en-
hancer of 1(II) collagen, and, in DNA cotransfectionConsistent with this model, a chondrocyte-specific dele-
tion of Smo results in decreased chondrocyte proliferation experiments, Sox5 and Sox6 increase Sox9 transactiva-
tion function (Lefebvre et al., 1998). This evidence sug-similar to that observed in Ihh-deficient mice. In chondro-
cytes lacking either Ihh or Smo, CyclinD1 expression is gested that Sox5 and Sox6 could also contribute to
chondrocyte differentiation. Such a hypothesis was con-markedly decreased, suggesting that Ihh regulation of
chondrocyte proliferation requires this cell cycle regu- firmed by the analysis of Sox5/Sox6 double-deficient
mice. Indeed, these mutant mice die at E16, displaying,lator. Conversely, gain-of-function experiments have
shown that activation of the Ihh signaling pathway is at that stage, a severe chondrodysplasia characterized
by a failure of chondrocyte progenitors to differentiatesufficient to promote chondrocyte proliferation (Long et
al., 2001). An interesting link between the Ihh pathway into hypertrophic chondrocytes. As a result of this dis-
ruption, there is no columnar organization of chondro-and the Fgf pathway is indicated by data showing that
either FGF18 or FGFR3 signaling can inhibit Ihh expres- cytes in the growth plate, and endochondral bone forma-
tion as a whole is affected (Smits et al., 2001). Thesion (Liu et al., 2002; Naski et al., 1998).
In addition to FGF and Ihh signaling, one other growth molecular mechanisms whereby these two factors, de-
void of any identifiable transactivation domains, affectfactor, C-type natriuretic peptide (CNP), has been shown
to affect chondrocyte proliferation. CNP belongs to a chondrocyte differentiation have not yet been eluci-
dated. Nevertheless, this study showed that severalsmall family of peptides that also includes ANP and
BNP. All these factors transduce their signals following transcription factors of the HMG family control the early
stages of chondrogenesis, from mesenchymal cells tobinding to receptors with guanylate cyclase activity (Ro-
senzweig and Seidman, 1991). CNP is expressed by chondrocyte progenitors and from chondrocyte progen-
itors to proliferating chondrocytes. This suggests that,many cell types, including chondrocytes. CNP-deficient
mice show dwarfism due to a delay in endochondral as for other lineages, such as the myoblast lineage,
molecules of the same family control the cascade ofossification. Deletion of the natriuretic peptide clear-
ance receptor Npr3 or overexpression of BNP both re- differentiation events. This does not exclude the possi-
bility that more HMG box-containing transcription fac-sult in skeletal overgrowth due to an increase in the
number of both hypertrophic and nonhypertrophic tors and other types of transcription factors are neces-
sary for chondrogenesis to occur.chondrocytes (Chusho et al., 2001; Jaubert et al., 1999;
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For instance, it was recently demonstrated that hyp- G protein-coupled receptor present in prehypertrophic
chondrocytes and, to a lesser degree, in proliferatingoxia-inducible factor-1 (HIF1) is required for chondro-
cyte survival, since mice lacking HIF1, specifically in chondrocytes. Three observations have demonstrated
unambiguously the critical role that PTHrP plays in regu-chondrocytes, display an increase in proliferation of
chondrocytes and an increase in chondrocyte death. lating hypertrophic chondrocyte differentiation. First,
the major phenotypic abnormality in PTHrP-deficientHowever, this survival function of HIF1 is partly due
to its regulation of Vegf, a gene required for vascular mice is dwarfism caused by premature differentiation
of nonhypertrophic chondrocytes into hypertrophicinvasion of the growth plate (Schipani et al., 2001). Other
transcription factors affect chondrocyte differentiation; chondrocytes (Karaplis et al., 1994). Second, metatarsal
bones cultured in vitro in the presence of PTHrP showthey include ATF-2 (Reimold et al., 1996), CREB (Long
et al., 2001), Ets-2, NFAT-1, and c-Fos. Overexpression delayed differentiation of the hypertrophic chondrocytes
(Lanske et al., 1996). Third, humans and mice harboringof c-Fos in chimeras leads to enhanced proliferation
and transformation of chondrocytes during develop- an activating mutation in PPR exhibit a delay in hypertro-
phic chondrocyte differentiation similar to that seen inment (Wang et al., 1991), whereas the absence of c-Fos
disrupts growth plate architecture with a significantly bone explants exposed to excess PTHrP (Schipani et
al., 1995; Schipani et al., 1997). Subsequently, gain-of-shorter zone of proliferating cells and an expanded re-
gion of hypertrophic cells (Wang et al., 1992). These function and loss-of-function experiments in chickens
and mice demonstrated that Pthrp expression is underdata imply a positive role of c-Fos in chondrogenesis
(Figure 2), whereas experiments in embryonic chick limb the control of Ihh, which is expressed by the prehyper-
trophic chondrocytes. By signaling to the cells of thebuds (Watanabe et al., 1997) and in murine chondro-
genic cells in vitro (Thomas et al., 2000) argue for an perichondrium, Ihh upregulates their synthesis of
PTHrP, thereby indirectly slowing down the process ofinhibitory function of c-Fos on nonhypertrophic chon-
drocyte differentiation. chondrocyte hypertrophy (St-Jacques et al., 1999; Vort-
kamp et al., 1996). Further analysis of Ihh-deficient miceThe transition from a nonhypertrophic chondrocyte to
a hypertrophic chondrocyte appears to be under the and chimeric mice generated using PPR-deficient ES
cells or PPR/Ihh double-deficient ES cells have estab-control of the canonical Wnt signaling pathway. Wnt5a
is expressed in the early chick limb perichondrium, while lished that Ihh also controls the differentiation of the
mesenchymal cells in the bone collar into osteoblastWnt5a or dominant-negative Frizzled misexpression in-
hibited the transition. Delay or acceleration of this transi- progenitors and that the distance between Ihh-express-
ing cells and PPR-expressing cells controls the site oftion point resulted in inhibition or acceleration of ossifi-
cation, indicating that this is a major checkpoint during chondrocyte hypertrophy as well as the location of the
bone collar (Chung et al., 2001).bone formation.
Hypertrophic Chondrocyte Differentiation Wnt signaling plays an important role in the regulation
of hypertrophic chondrocyte biology. Wnt4 is expressedThis group of chondrocytes comprises two subpopula-
tions: the prehypertrophic chondrocytes located below in periarticular chondroblasts, and the intracellular me-
diator -catenin is expressed in the perichondrium andthe proliferating chondrocytes and the fully differenti-
ated hypertrophic chondrocytes. Prehypertrophic chon- hypertrophic chondrocytes (Kawakami et al., 1999; Hart-
mann and Tabin, 2001). Misexpression of Wnt4 or consti-drocytes are larger than proliferating chondrocytes; they
undergo growth arrest and express Ihh, FGFR1, and tutively active -catenin accelerated the nonhypertro-
phic to hypertrophic transition and resulted in slightlyCbfa1, at least during development, while 1(II) collagen
expression is decreased. The differentiated hypertro- advanced ossification, while misexpression of domi-
nant-negative forms of the Wnt receptors Frizzled1 andphic chondrocyte groups are even larger cells that will
die through apoptosis. These cells no longer express 7 had opposite effects. Misexpression of Wnt5a, which
is normally expressed in the perichondrium, caused a1(II) collagen and are characterized by the expression
of1(X) collagen, a gene expressed only by this subpop- delay in the transition from prehypertrophic to hypertro-
phic chondrocyte, resulting in a mild delay in ossifica-ulation of chondrocytes. Hypertrophic chondrocytes are
also characterized by the expression of Vegf and by a tion. Though all manipulations led to shorter bones, ex-
pression levels of Pthrp and Ihh were normal, indicatingresidual and weak Cbfa1 expression during develop-
ment. In the absence of hypertrophic chondrocytes, en- that Wnt signaling is either independent or downstream
of the PTHrP/Ihh loop. Lastly, misexpression studiesdochondral bone formation cannot occur. Indeed, the
hypertrophic chondrocytes are surrounded by a specific in chickens have indicated that Delta1, a Notch ligand
expressed only in hypertrophic chondrocytes, can in-mineralized ECM that somehow is required for the vas-
cular invasion that will bring in osteoblast progenitors. hibit the transition of nonhypertrophic chondrocytes to
the hypertrophic stage (Crowe et al., 1999). Further eluci-At the same time that the field of nonhypertrophic chon-
drocyte differentiation was opened up by the finding dation of the role of the Notch/Delta pathway in chondro-
genesis awaits loss-of-function experiments.that activating mutations in FGFR3 cause ACH, the field
of hypertrophic chondrocyte differentiation expanded The process of endochondral ossification takes place
at a highly variable, age-dependent rate in wild-typewith the identification of parathyroid hormone-related
peptide (PTHrP) as an inhibitor of chondrocyte hyper- animals. Two critical factors, growth hormone produced
by the pituitary gland and IGF1 produced by proliferatingtrophy.
Pthrp is a broadly expressed gene, which, in develop- and hypertrophic chondrocytes, among many other tis-
sues, appear to act largely independently to control theing cartilage, is present in cells of the perichondrium.
PTHrP is a secreted molecule transducing its signal fol- rate of chondrocyte proliferation and, therefore, the rate
of linear growth. Since mice lacking both the growthlowing its binding to the PTH/PTHrP (PPR) receptor, a
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hormone receptor and IGF1 are only twice the size of ectopic joint-like structures. Histological analysis of
these joints showed that there was a reversal of chon-the smallest known mammal, these two factors appear
to be the major regulators of linear bone growth and drogenic differentiation. The infected cells expressed
1(III) collagen, a gene expressed by articular chon-body size in mammals (Lupu et al., 2001).
The field has also made significant progress in under- drocytes and joint-specific markers, such as Chordin,
Autoaxin, and Gdf5, while a downregulation of severalstanding the transcriptional control of chondrocyte hy-
pertrophy. Cbfa1/Runx2 is a member of the runt family chondrogenic markers, such as 1(II) collagen, ag-
grecan,1(IX) collagen, Sox9, and Bmp4, was observed.of transcription factors that, besides its role in os-
teogenesis, is required for hypertrophic chondrocyte The third line of evidence is that, in vitro, limb mesenchy-
mal cells infected with a Wnt14 retrovirus could notdifferentiation. In Cbfa1-deficient mice hypertrophic
chondrocytes are absent from several, although not all, differentiate into proteoglycan-producing, alcian blue-
positive cartilage nodules (Hartmann and Tabin, 2001).skeletal elements (Inada et al., 1999; Kim et al., 1999).
Cbfa1 is expressed in prehypertrophic chondrocytes, Although these results were obtained by misexpression
experiments, their conclusions are convincing. Theand its constitutive expression in nonhypertrophic chon-
drocytes induces hypertrophic chondrocyte differentia- value of these experiments could certainly be enhanced
by the validation that a gene deletion experiment intion, Ihh expression, and, eventually, endochondral
bone formation (Takeda et al., 2001; Ueta et al., 2001). mouse provides. However, given that joint formation is
a complex process that involves multiple genes possiblyThus, a regulatory loop seems to exist wherein Cbfa1
directly or indirectly regulates Ihh expression. In turn Ihh belonging to the same family, the absence of a joint
phenotype in Wnt14-deficient mice will not contradictregulates Cbfa1 expression in the mesenchymal cells of
the bone collar. Indeed, in Ihh-deficient mice, Cbfa1 is these results. Other examples exist of differentiation
genes whose deletion failed to show the expected phe-not expressed in the cells of the bone collar, and, as a
result, osteoblast differentiation does not occur in long notype due to functional substitution by other genes of
the same family coexpressed in the same cell (Rudnickibones of these mice (St-Jacques et al., 1999). These
molecular observations illustrate the tight interrelation- et al., 1992).
Growth/differentiation factor 5 (GDF5), also called car-ship that takes place between chondrocytes and osteo-
blasts during endochondral ossification (Figure 1). The tilage-derived morphogenetic protein 1 (CDMP1), is an-
other molecule that affects joint formation in mouse andpresence of hypertrophic chondrocytes in several skele-
tal elements in Cbfa1-deficient mice indicates that other humans. GDF5 is a member of the TGF/BMP superfam-
ily of growth factors. Within this family its closest rela-transcriptional inducers of hypertrophic chondrocyte
differentiation must exist. tives are GDF6 and GDF7, and all three are expressed
in developing joints. Mutations in Gdf5 in mice causeArticular Chondrocyte Differentiation
We described earlier how, at the location of the future the classic brachypodism phenotype, a segmentation
defect of the phalangeal skeletal elements (Grunebergjoint the interzone forms, layers of high or low cell den-
sity arise, the joint cavity expands, and the articular and Lee, 1973; Landauer, 1952; Storm et al., 1994). In
humans, mutations in GDF5/CDMP1 cause several dif-chondrocytes differentiate (Figure 3). Molecular embry-
ological studies in chicken along with human and mouse ferent types of chondrodysplasia (Polinkovsky et al.,
1997; Thomas et al., 1997; Thomas et al., 1996). Thegenetics analyses have identified several molecules in-
volved in joint formation. However, we still know much main characteristics of these phenotypes in mice and
humans are a shortening of the limbs, abnormal jointless about articular chondrocyte differentiation than
about the differentiation of the other chondrocyte popu- formation, and a reduction in the number of bones in
digits 2–5 due to the disappearance of joints and fusionlations. Nor do we know yet whether the molecular mark-
ers that have already been identified specifically regu- of proximal and medial phalange skeletal elements. The
temporal and spatial pattern of Gdf5 expression is alsolate articular chondrocyte differentiation and no other
aspect of chondrogenesis. Due to the high prevalence consistent with a function as regulator of joint develop-
ment. During mouse development Gdf5 is expressed inof osteoarthritis, which is characterized by a progressive
loss of articular cartilage resulting in a loss of joint func- the prospective shoulder and elbow regions at E11. At
E12 Gdf5 becomes expressed in the developing digitstion, this line of research is expanding.
Wnt14 is the molecular marker that is currently viewed and within the digit in the region where joints will form
(Figure 3). As skeletal development proceeds Gdf5 ex-as the earliest “inducer” of joint formation. This notion
is based on several lines of evidence. The first one stems pression extends to virtually all future joints in the limbs
(Storm et al., 1994). GDF5 protein beads can rescuefrom Wnt14 pattern of expression (Figure 3). In chick,
Wnt14 is expressed in a single stripe in the presumptive the Gdf5 null digit joint fusion phenotype (Storm and
Kingsley, 1999); however, GDF5 overexpression in earlyjoint region at day 5 of embryonic development. Two
days later Wnt14 is expressed in the mesenchymal cells mouse and chick wild-type limbs also results in joint
fusions, presumably by causing cartilage overgrowthsurrounding the cartilage elements as well as in a bipar-
tite stripe within the region that contains presumptive (Merino et al., 1999; Storm and Kingsley, 1999).
The effects of GDF5 overexpression in vivo can bearticular chondrocytes. At later stages Wnt14 will remain
expressed in cells of the joint and in the mesenchymal antagonized by the BMP antagonist Noggin, and GDF5
binds to Noggin in vitro (Merino et al., 1999). Noggin-cells surrounding the developing elements but not in
the perichondrium. Such a temporal and spatial pattern deficient mice have no joints at all as well as widened
bones, caused by cartilage overgrowth (Brunet et al.,of expression is consistent with a “joint inducer” func-
tion for Wnt14. The second line of evidence favoring 1998). Gdf5 expression is absent from presumptive
joints in these mice, and Noggin overexpression inducesthis hypothesis is that retroviral Wnt14 misexpression
in developing chick limbs induces the appearance of ectopic Gdf5 (Merino et al., 1999), reinforcing the notion
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that Gdf5 lies downstream of Noggin during joint forma- mice regained a normal appearance. These results re-
vealed that MMP9 function in cartilage is to favor carti-tion. Lastly, the study in chick mentioned earlier showed
that Wnt14 misexpression induces Gdf5 expression, lage removal and to promote angiogenesis. Wild-type
bone marrow transplantation into MMP9-deficient micesuggesting that Gdf5 also lies downstream of Wnt14
during joint formation (Hartmann and Tabin, 2001). Since rescued this phenotype. The MMP9-expressing cells of
bone marrow origin were called chondroclasts, whoseactivated FGFR signaling in chondrocytes also leads to
joint fusions (Wang et al., 2001), it will not be surprising function is to resorb cartilage. Chondroclasts differ from
osteoclasts in their localization at the chondro-osseousto see the same confluence of the Wnt, FGF, and BMP
signaling pathways in the specification of joint forma- junction and by the fact that they express more MMP9
but less Trap than do osteoclasts (Engsig et al., 2000;tion, as is seen in other developmental events (Wilson
et al., 2001). Vu et al., 1998).
To further study the role of MMP9 in vitro, angiogenicA third signal transduction pathway clearly involved
in joint development and/or in the maintenance of the assays were performed using hypertrophic chondro-
cytes from wild-type or mutant mice cultured in collagenarticular chondrocyte phenotype is the TGF signaling
pathway. One of the transcription factors involved in gels containing vascular endothelial cells. In these
assays hypertrophic chondrocytes from MMP9-defi-TGF signal transduction is Smad3 (Heldin et al., 1997).
TGF1, -2, -3, their receptors, and Smad3 are expressed cient mice induced proliferation and migration of vascu-
lar endothelial cells toward the cartilage in a delayedin cells of the perichondrium and in articular chondro-
cytes. Mutant mice harboring a disruption of Smad3 manner compared to wild-type cells, suggesting that
MMP9-deficient chondrocytes do not release in a timelydevelop over time a degenerative joint disease mimick-
ing human osteoarthritis. Molecular analysis of this phe- fashion and/or at an appropriate level one or several
angiogenic factors. One of these angiogenic factors isnotype showed ectopic 1(X) collagen expression in
articular chondrocytes and increased hypertrophic dif- VEGF. Its involvement was uncovered later, since VEGF
sequestration by a soluble receptor in wild-type miceferentiation in growth plate cartilage, suggesting that
TGFs function as inhibitors of articular chondrocyte nearly completely blocked vascular invasion, leading to
an expansion of the zone of hypertrophic chondrocytes,differentiation (Yang et al., 2001). It is not clear at the
present time whether this signaling pathway acts during and reduced bone length, a phenotype similar to the
one observed in MMP9-deficient mice. All these abnor-joint development or only after the joint is formed, and
we do not know whether it interacts or antagonizes the malities disappeared following cessation of the anti-
VEGF treatment (Gerber et al., 1999). Similar results wereWnt14/Gdf5 pathway.
obtained from genetic experiments in mice harboring a
chondrocyte-specific deletion of Vegf (Haigh et al.,Intermission: Vascular Invasion
2000). Thus, the emerging model is that VEGF synthe-of Hypertrophic Cartilage
sized by hypertrophic chondrocytes is present in theThe switch from a cartilage template to a bona fide
cartilaginous ECM and, upon degradation of this ECMbone during endochondral bone formation is not a mere
by MMP9, VEGF is released and can bind to its receptorswitch of cell phenotypes. There is no evidence in vivo
on chondroclasts, vascular endothelial cells, and osteo-for transdifferentiation of chondrocytes into osteoblasts
blasts, thereby favoring vascular invasion and cartilage(Takeda et al., 2001). This switch, rather, requires a vas-
replacement by bone (Figure 4).cular step. Vascular invasion occurs only in the ECM
As mentioned earlier, Cbfa1, whose role during chon-surrounding the hypertrophic chondrocytes. The blood
drogenesis has already been presented, is also neces-vessels coming from the bone collar bring, into the cen-
sary for vascular invasion to occur independently of itster of the future bone, both osteoblast and osteoclast
role in inducing chondrocyte hypertrophy. Indeed, thereprogenitors. The cartilaginous ECM is then replaced by
is no vascular invasion in any skeletal elements of Cbfa1-a bone ECM rich in type I collagen, a molecule secreted
deficient mice, even in the ones that do contain hypertro-by osteoblasts. Many studies analyzing this sequence
phic chondrocytes (Zelzer et al., 2001). In these mutantof events from vascular invasion to osteogenesis have
mice the upregulation of Vegf expression that is normallyhighlighted the interplay between two types of mole-
observed in the hypertrophic chondrocytes of wild-typecules in this process: proteases and growth factors. To
mice does not occur and VEGF receptors that are ex-date, the role of metalloproteinase 9 (MMP9) or gela-
pressed in wild-type perichondrium are not expressed.tinase B and VEGF have been most extensively de-
Lastly, Cbfa1 binds to and increases the activity of thescribed.
Vegf promoter in vitro, and forced expression of Cbfa1MMP9 is highly expressed in osteoclasts during devel-
in cultured cells leads to Vegf expression and VEGFopment and after birth. It encodes a secreted protease.
production. These data suggest that, in the hypertrophicThe only phenotypic abnormality of MMP9-deficient
zone of cartilage, Vegf lies downstream of Cbfa1 (Zelzermice is a slight, but significant, shortening of their long
et al., 2001) (Figure 1).bones (Vu et al., 1998). Although modest, this phenotype
uncovered a biological pathway of great importance for
skeletal development. Histological analysis of long The Outcome: Osteogenesis, Its Genetic
and Molecular Controlbones from MMP9-deficient mice before weaning re-
vealed a massive and transient lengthening of the zone Bone contains two specific cell types, the osteoblast,
or bone-forming cell, and the osteoclast, or bone-resorb-of hypertrophic chondrocytes. However, after three weeks
of age, the excess hypertrophic chondrocytes died ing cell. As will be presented below, there is more than
a close physical proximity between osteoblasts and os-through apoptosis, vascularization and osteogenesis
occurred, and the growth plate and long bones of these teoclasts in bone. Indeed, some genes expressed in
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Figure 4. Sequence of Events during Vascu-
lar Invasion
Expression of Cbfa1 and other transcription
factors in prehypertrophic chondrocytes in-
duces Vegf expression in hypertrophic chon-
drocytes. VEGF is trapped in the matrix. Dur-
ing vascular invasion MMP9 secreted by the
chondroclasts releases VEGF from the ma-
trix. VEGF can now bind to its receptor on
endothelial cells and initiate vascular invasion
on osteoblasts and, presumably, on chon-
droclasts.
osteoblast progenitors, osteoblasts, and unrelated cell The bone morphogenetic proteins (BMPs) form a sub-
family of growth factors among the TGF superfamily.types actually control osteoclast differentiation. How-
ever, the relationship between these two bone cell types They have long been considered the primary suspects
to be in vivo bone inducers. This suspicion was baseddoes not extend to the regulation of their functions (Cor-
ral et al., 1998). The osteoblast is a cell of mesenchymal on their pharmacological, but nevertheless stunning,
ability to induce ectopic bone formation (Reddi 1997).origin that shares a common precursor with chondro-
cytes (Ducy et al., 1997). Given the existence of their The fact that they induce bone formation by recapitulat-
ing the entire sequence of events occurring during endo-common progenitor, it is not surprising that osteoblasts
and chondrocytes use common regulatory genes such chondral ossification is a feature whose importance can-
not be emphasized enough (Reddi 1997; Wang et al.,as Ihh and Cbfa1. The site of origin of osteoblasts is
still a matter of debate, although the analysis of Ihh- 1990). Indeed, this extraordinary bone forming ability,
shared by BMP2, -4, -6, and -7, may be seen as a reflec-deficient mice and chimeric experiments using PPR/
and PPR/Ihh/ ES cells strongly suggest that they origi- tion of their function as skeletal mesoderm inducers
rather than as “bone inducers” per se (Capdevila andnate from the bone collar and reach the center of the
future skeletal element via blood vessel invasion (see Izpisua Belmonte, 2001). Genetic analysis of BMP func-
tion has shown that, as expected for skeletal mesodermabove and Figure 1). The osteoclast, on the other hand,
is a cell type of monocytic origin, which shares a com- inducers, they play a critical role during skeletal pat-
terning by controlling the appearance and shape of vari-mon precursor with macrophages. It differentiates
within the bone marrow, and its differentiation is under ous skeletal mesenchymal condensations. They also
favor chondrocyte differentiation (Zou et al., 1997). How-the control of secreted molecules present in the bone
microenvironment. Mononucleated osteoclast precur- ever, so far, it has not been possible, using gene deletion
experiments, to demonstrate that any BMP favors os-sors cross the mesenchyme surrounding the skeletal
elements and migrate together with endothelial cells teoblast differentiation independently of its function as
mesoderm inducer and chondrogenic inducer. Thesethrough the nearest bone collar at the time of vascular
invasion (Figure 1). results, being negative in nature, have to be interpreted
cautiously. The ability to perform cell-specific deletionsOsteoblast Differentiation
As already mentioned, Ihh and FGF18 are the only of one or several Bmps should help address this ques-
tion more rigorously in the future.growth factors for which genetic evidence demonstrates
an essential role during osteoblast differentiation. In Ihh- The only BMP-deficient mice that display an unequiv-
ocal bone phenotype are the BMP3 mutant mice. Sur-deficient mice there are no Cbfa1-positive cells in the
bone collar, and neither is there any osteoblast differen- prisingly, these mutant mice have more, rather than less,
bone. There is not yet information on the mechanismstiation in the skeletal elements that should ossify through
endochondral ossification. It is still not clear whether leading to this high-bone mass phenotype; in particular,
it is not known whether BMP3 affects osteoblast differ-this absence of osteoblasts is a direct or indirect conse-
quence of the absence of Ihh signaling. The spatial re- entiation or proliferation in vivo (Daluiski et al., 2001).
To date, the only evidence that BMPs may affect specifi-striction of this Ihh function to skeletal elements whose
ossification is of endochondral nature indicates that cally osteoblast proliferation is indirect. Mice deficient
in Tob, a member of a novel antiproliferative proteinother growth factor(s) may control osteoblast differenti-
ation in skeletal elements that ossify through intramem- family, have a high bone mass phenotype secondary to
an increase in osteoblast proliferation. They also showbranous ossification.
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an increase in orthotopic bone formation in response to in vivo, since ectopic expression of Cbfa1 leads to endo-
chondral ossification in parts of the skeleton that nor-BMP2. Tob associates with Smad1, -5, and -8, the Smad
mally will never ossify (Takeda et al., 2001; Ueta et al.,utilized in BMP signaling, but not with Smad2 or -3,
2001). Finally, Cbfa1 is also required for osteoblast func-which are preferentially used in TGF signaling (Yoshida
tion beyond differentiation (Ducy et al., 1999; Liu et al.,et al., 2000). If Tob does act by inhibiting BMP signaling
2001). These functions along with its role during hyper-without affecting any other signaling pathway, then this
trophic chondrocyte differentiation and vascular inva-study demonstrates a role for BMPs in osteoblast prolif-
sion identify Cbfa1 as the most pleiotropic regulator oferation.
skeletogenesis.TGF, which is significantly more abundant in bone
The central role played by Cbfa1 during osteoblastmatrix than the BMPs, also plays a role during osteoblast
differentiation raises several questions. The first ques-differentiation. Osteoblast-specific overexpression of
tion is, how is Cbfa1 expression regulated? Although weTGF2 in mice results in a low-bone mass phenotype,
still have few answers to this question, there is geneticwith an increase in the number of osteocytes, i.e., osteo-
evidence for at least three genes encoding transcriptionblasts embedded in bone ECM (Erlebacher and Derynck,
factors regulating Cbfa1 expression. Msx2, which en-1996). In addition, deletion of the gene encoding latent
codes a homeobox-containing transcription factor, isTGF binding protein 3, a protein that limits TGF bio-
expressed in osteoblasts during development. The roleavailability, results in an increase in bone mass and an
of Msx2 during skull formation was first uncovered byosteoarthritis phenotype (Dabovic et al., 2002).
human genetic studies. Indeed, one syndrome charac-The most abundant growth factors present in the bone
terized by increased bone formation around the cranialECM are the insulin-like growth factors 1 and 2 (IGF1 and
suture, Boston-type craniosynostosis, is caused by an2). Both IGF1 and 2 stimulate osteoblast proliferation in
activating mutation in MSX2 (Ma et al., 1996). Msx2 inac-vitro (Canalis, 1993). In vivo, overexpression of IGF1 in
tivation in mice causes a marked delay of ossificationosteoblasts results in a modest and transient increase
in the bones of the skull and an overall decrease in bonein bone mass (Zhao et al., 2000).
volume. This phenotype is accompanied by a downregu-The transcriptional control of osteoblast differentia-
lation of Cbfa1 expression, indicating that Msx2 directlytion is dominated by one major genetic pathway that is
or indirectly regulates Cbfa1 expression (Satokata etstill incompletely elucidated and that comprises Cbfa1/
al., 2000). Bapx1, another homeobox protein encodingRunx2 as its centerpiece. Cbfa1 is the earliest and most
gene, is required for axial skeleton formation. In Bapx1-specific molecular marker of osteoblast differentiation
deficient mice Cbfa1 expression is downregulated in theand a differentiation factor in the osteoblast lineage.
axial skeleton (Tribioli and Lufkin, 1999), suggesting thatThe different lines of evidence supporting this claim are
Bapx1 is another activator of Cbfa1 expression. At leastsummarized here. Starting at E10.5 of mouse embryonic
one gene seems to inhibit Cbfa1 expression during de-development, Cbfa1 is expressed in lateral plate meso-
velopment. Inactivation of Hoxa-2, encoding a homeo-derm and in all cells of the mesenchymal condensations
box-containing protein, results in ectopic Cbfa1 expres-prefiguring the future skeletal elements. Between E10.5
sion and ectopic bone formation in the second branchialand E12.5 these Cbfa1-positive cells express molecular
arch (Kanzler et al., 1998). This area of osteoblast biologymarkers of chondrocyte [1(II) collagen] and of undiffer-
is still in its infancy, and many more genes will be identi-entiated mesenchymal cell and osteoblast progenitors
fied as regulators of Cbfa1 expression.[1(I) collagen]; for this reason they were called osteo-
The second question raised by the central role ofchondroprogenitor cells (Ducy et al., 1997). After E12.5,
Cbfa1 during osteoblast differentiation stems from itsCbfa1 expression steadily increases, first in osteoblast
pattern of expression. Cbfa1 expression can be de-progenitors and then in bona fide osteoblasts, while it
tected in E10.5 mouse embryos, and, yet, there will bewill progressively decrease in prehypertrophic chondro-
no osteoblast identifiable before E14.5. How can this
cytes until it becomes undetectable in these cells at
delay be explained? Three possible mechanisms, which
birth (Inada et al., 1999; Kim et al., 1999; Takeda et al.,
are not necessarily mutually exclusive, can be proposed.
2001). Cbfa1 is necessary for osteoblast differentiation; The first mechanism could be that Cbfa1 controls the
this was unambiguously demonstrated by its inactiva- expression of other genes encoding osteoblast-specific
tion in mice. Indeed, Cbfa1-deficient mice have a carti- transcription factors. One such factor is Osterix (Osx),
laginous skeleton without any osteoblasts, as their dif- a novel zinc finger-containing protein expressed in os-
ferentiation is arrested as early as E12.5 (Komori et al., teoblast progenitors and whose absence causes a phe-
1997; Otto et al., 1997). In contrast to Ihh, Cbfa1 is notype which is similar to, but less severe than, the
required for osteoblast differentiation throughout the one caused by Cbfa1 deficiency. The fact that Cbfa1 is
skeleton, whether the bones formed through endochon- expressed in Osx-deficient mice and that Osx is not
dral or intramembranous ossification. In Cbfa1/ mice expressed in Cbfa1-deficient mice is an indication that
there is a defect in osteoblast differentiation limited to it is downstream of Cbfa1 (Nakashima et al., 2002). On-
bones forming through intramembranous ossification going work from several laboratories indicate that the list
(Otto et al., 1997). This phenotype is called cleidocranial of factors acting downstream of Cbfa1 during osteoblast
dysplasia (CCD) in humans, and Cbfa1 is mutated in differentiation is still incomplete. A second mechanism
most CCD patients (Lee et al., 1997; Mundlos et al., could be that the transactivation function of Cbfa1 re-
1997). Moreover, Cbfa1 is sufficient to induce osteoblast quires a coactivator whose expression is initiated only
differentiation. This is true in cell culture, where forced later during development. Lastly, a third mechanism
expression of Cbfa1 in skin fibroblasts leads to osteo- could be that Cbfa1 transactivation function is inhibited
early during development by a protein either binding toblast-specific gene expression (Ducy et al., 1997), and
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the same binding site or binding to Cbfa1 itself. Consis- suggesting that Lrp5 mutations may in fact have uncov-
ered a function for Wnt proteins in the control of perinataltent with this model, a recently identified zinc finger-
containing protein called AJ18 has been shown to inhibit and postnatal osteoblast proliferation. Since Wnt pro-
teins preferentially use the Lef/Tcf family of transcriptionCbfa1 function in cell culture by competing for binding
to the same consensus sequence (Jheon et al., 2001). factors to mediate their functions, the possibility exists
that Wnt proteins binding to a Frizzled-Lrp5 receptorIt is likely that all three mechanisms of regulation may
be at work and that several additional molecules are complex affects osteoblast proliferation and gene expres-
sion in a Cbfa1-independent, but Lef/Tcf-dependent, man-involved in the Cbfa1-dependent pathway controlling
osteoblast differentiation. ner. This would be reminiscent of the crucial role the
Wnt signaling pathway plays during skin development.Finally, the third question raised by Cbfa1’s multiple
functions is to determine whether there is any Cbfa1- A note of caution should be added here. There is not
yet an in vivo demonstration that any Wnt protein is theindependent pathway controlling osteoblast differentia-
tion or proliferation. The first indications that such a ligand of Lrp5 responsible for its functions in osteoblast
biology. Furthermore, by analogy to Lrp1, Lrp5 may bindmechanism may exist came from the analysis of various
mutant mouse strains. For instance, Dlx5, which en- to several ligands of different classes with high affinity.
Nevertheless, these data suggest that, while osteoblastcodes another homeobox-containing protein, is ex-
pressed in mesenchymal condensations undergoing in- differentiation is essentially a Cbfa1-directed process,
osteoblast proliferation is not.tramembranous ossification. In Dlx5-deficient mice there
is normal Cbfa1 expression and, yet, delayed skull for- Beyond osteoblast biology itself there is a simple les-
son to be (re)learned from the role of Lrp5 signaling inmation, suggesting that either Dlx5 is downstream of
Cbfa1 or that it acts in a Cbfa1-independent manner bone formation. Lrp5, a priori, has none of the attributes
of a gene to be studied in the context of skeletal biology.(Acampora et al., 1999). Another suggestive indication
that bone formation can be affected in a Cbfa1-indepen- It is ubiquitously expressed, without apparent regula-
tion, and, if it were not for the Wnt connection thatdent manner came from two studies dealing with post-
natal development. Transgenic mice overexpressing came into play relatively recently, there would be no
real reason to get interested in this gene. This paucityFra-1, a c-Fos-related protein that lacks any identifiable
transactivation domain, or FosB, a truncated form of of appealing features dramatically contrasts with its
function in skeletal biology and underscores how impor-FosB arising from alternative splicing of the FosB tran-
script, both exhibit an increase in osteoblast numbers tant hypothesis-driven studies will remain, even in the
genomic and postgenomic era (Gong et al., 2001; Littleafter birth, leading to increased bone formation and,
ultimately, increased bone mass despite normal levels et al., 2002).
Osteoclast Differentiationof Cbfa1 expression (Jochum et al., 2000; Sabatakos et
al., 2000). These studies support the hypothesis that Osteoclasts are multinucleated, terminally differentiated
cells that are endowed with the unique capacity to de-some aspect of osteoblast biology can be altered inde-
pendently of Cbfa1 expression. grade mineralized tissues. It is the last specific cell type
of the skeleton to appear during development, and it isDirect proof that osteoblast differentiation and prolif-
eration are regulated by different pathways came re- the principal, almost exclusive, resorptive cell present
in the bone. This may be the cell type for which we knowcently from the study of a gene with no apparent relation-
ship to skeletal biology. This gene, LRP5, encodes a the most, although our knowledge is still incomplete.
The osteoclast plays a central role not only during bonereceptor called LDL-receptor-related protein 5, which
is ubiquitously expressed. LRP5 maps in the human development but also in the regulation of bone mass
throughout life. The increased activity of osteoclastsgenome to chromosome 11q13, where two human dis-
eases, osteoporosis-pseudoglioma syndrome and the caused by estrogen withdrawal causes bone loss and
osteoporosis, a frequent low-bone mass disorder inhigh-bone mass syndrome, map. Classical human ge-
netic studies demonstrated that osteoporosis-pseu- postmenopausal women leading to structural instability
and a high fracture risk. On the other hand, osteopetrosis,doglioma syndrome is due to a deletion or inactivation
of LRP5, whereas the high-bone mass syndrome is a bone disease characterized by increased bone mass
and obliteration of the bone marrow cavity, is causedcaused by what is presumably an activating mutation
of LRP5 (Gong et al., 2001; Little et al., 2002). Inactivation by impaired osteoclast differentiation and/or function.
Osteopetrosis is a rare human disease but a frequentof Lrp5 in mice was performed for a totally different
reason (Kato et al., 2001), yet the main phenotypic ab- phenotype in naturally occurring and genetically engi-
neered mouse mutants. Analysis of these mutant mousenormality in these mutant mice was a low-bone mass
phenotype, and molecular studies showed that Lrp5 in- strains has helped tremendously to dissect the regula-
tory pathways leading to osteoclast differentiationactivation decreases osteoblast proliferation and bone
formation without affecting Cbfa1 expression (Kato et (Wagner and Karsenty, 2001). Osteoclast biology has also
benefited from the ability to generate this cell type in vitroal., 2001).
Lrp5 is the mammalian homolog of the Drosophila with and without the support of osteoblastic stromal cells.
Osteopetrotic mice and in vitro osteoclastogenesis haveprotein Arrow, which is a coreceptor for Wingless (Wehrli
et al., 2000), and there are already clues regarding the been critical in identifying many genes encoding signaling
molecules or transcription factors. We now know thatsignal transduction pathway and the transcriptional acti-
vators involved. In cell culture Lrp5 also acts as a core- these genes have important roles as regulators of osteo-
clast differentiation and function (Figure 5). Here, we willceptor for Wnt proteins (Mao et al., 2001), and Lrp5 can
directly bind Wnt proteins in vitro (Kato et al., 2001), only briefly describe the origin of the osteoclast and will
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Figure 5. Molecular Mechanisms and Regulation of Osteoclast Differentiation from Hematopoietic Stem Cells
The individual molecules presumably acting at different stages during precursor cell proliferation and differentiation are depicted: transcription
factors, red; signaling molecules, blue. Mouse mutants lacking factors that function early in the lineage, such as PU.1, M-CSF, and c-Fos,
are osteopetrotic and lack either macrophages and osteoclasts or only osteoclasts. Mice lacking genes that act later in the lineage are still
osteopetrotic but have substantial numbers of osteoclasts that are not functional. The last class of mutants have morphologically normal
osteoclasts but fail to resorb bone. CTR, calcitonin receptor; CAII, carbonic anhydrase II; ClC-7, chloride channel-7.
concentrate on new insights into the molecular mecha- sealing zone surrounds a convoluted membrane area
called the “ruffled border,” which is formed as a resultnisms of osteoclast differentiation. We refer to recent
reviews for the molecular aspects of osteoclast function of insertion of vesicles and active directional secretion.
Protons and proteases secreted into this compartment(Chambers 2000; Duong and Rodan, 2001; Manolagas,
2000; Teitelbaum, 2000). between the cell and the bone surface dissolve mineral
and digest the organic compounds of bone. Therefore,How does a cell become an osteoclast, and how does
it function? Originally the osteoclast was believed to derive efficient bone resorption requires continuous cytoskele-
tal reorganization for migration, polarization on the bonefrom osteoprogenitors, but we now know through numer-
ous in vivo and in vitro experiments that the osteoclast is surface, and regulation of vesicular transport, a complex
regulatory process orchestrated by many gene prod-derived from monocyte/macrophage precursors (Cham-
bers, 2000). During development mononucleated osteo- ucts, whose functions are only partly understood. Re-
cent reviews nicely cover this topic and also discussclast precursors enter the mesenchyme surrounding the
bone rudiments, divide, and differentiate into tartrate- possible new strategies to efficiently block bone resorp-
tion for therapeutic interventions (Duong and Rodan,resistant acid phosphatase (TRAP)-positive cells that
migrate together with endothelial cells through the na- 2001). We will therefore focus our discussion on the
molecules instructing putative progenitor cells to be-scent bone collar. These cells then invade the calcified
cartilage; they fill the core of the diaphysis while fusing come “certified professional” osteoclasts.
Over ten years ago it was recognized that bone marrowinto multinucleated cells and differentiating into mature
osteoclasts. As a consequence the core of the bone stromal cells or their osteoblastic derivatives are required
for the in vitro differentiation of macrophage precursorsand a bone marrow cavity develops. Early on, it was
realized that the signals leading to the complex resorp- into osteoclasts (Udagawa et al., 2000). It is now clear that
two molecules expressed in these osteoblast/stromal cellstive patterns observed during development could have
been caused by local cells such as osteocytes and are essential and sufficient for osteoclastogenesis: macro-
phage-colony-stimulating factor (M-CSF) and receptor ac-bone-lining osteoblastic/stromal cells. These insights
provided the basis for the development of a powerful tivator of NF-B ligand (RANKL), also known previously
as OPG ligand (OPGL), osteoclast differentiation factorcoculture system, which allowed the derivation of func-
tional osteoclasts in vitro and which was strictly depen- (ODF), or TRANCE. However, as emphasized below,
these molecules are not osteoblast specific, thus raisingdent on the presence of inductive cells and hormones
(Suda et al., 1999). the hypothesis that the regulation of osteoclastogenesis
may be more complex than a simple tale of cell-cellAlthough osteoclasts share some cell surface markers
with macrophages, they also express high levels of interaction in the bone microenvironment. M-CSF is es-
sential for macrophage differentiation and survival. ItTRAP, vitronectin, and calcitonin receptors that are ab-
sent from macrophages. Most importantly, osteoclasts binds to its receptor, c-Fms, present also on osteoclast
precursors, thereby providing the signals for their sur-cultured ex vivo are able to resorb bone within hours,
whereas macrophages cannot. What are the mecha- vival and proliferation. The genetic proof for the impor-
tance of M-CSF in the macrophage/osteoclast lineagenisms responsible for activating osteoclasts and making
them resorb bone? Briefly, activation starts with osteo- came from the study of a classical mouse mutation, the
osteopetrotic op/op mouse, which carries an inactivat-clast adhesion to the mineralized bone matrix, thereby
forming a tight-sealing zone that encloses the resorption ing point mutation in the M-CSF gene (Yoshida et al.,
2000). These mutant mice lack mature macrophages andlacuna, frequently compared to a giant lysosome. The
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osteoclasts, and their osteopetrosis cannot be cured by soluble recombinant RANK suppresses osteoclast de-
velopment, and antibodies to RANK can stimulate os-bone marrow transplantation, while systemic adminis-
teoclast formation (Hsu et al., 1999). As predicted, micetration of M-CSF can (Felix et al., 1990). The nuclear
lacking RANK are osteopetrotic and have growth platetargets downstream of M-CSF-receptor signaling will
alterations characterized by dysplastic cartilage (Dou-be discussed below.
gall et al., 1999). Moreover, they fail to develop lymphThe second factor, RANKL was discovered only fol-
nodes, although T cell and dendritic cell numbers arelowing the identification of its inhibitor, termed osteo-
normal. Finally, the observations that transgenic overex-protegerin (OPG) or osteoclast inhibitory factor (OCIF).
pression of OPG, loss of RANKL, and loss of RANK allThis soluble TNF receptor-like molecule, which inhibits
lead to extreme thinning of cortical bone suggest thatosteoclast development, was identified independently
this system constitutes an important pathway regulatingby two groups (Simonet et al., 1997; Yasuda et al., 1998).
cortical bone formation (Dougall et al., 1999; Kong etTransgenic mice with increased circulating OPG devel-
al., 1999).oped a severe osteopetrosis, while OPG-deficient mice
The signaling cascade downstream of RANK/RANKLare osteoporotic due to increased osteoclasts (Bucay
is on its way to being elucidated (Figure 6). Severalet al., 1998; Mizuno et al., 1998). Some of the mice also
TNF receptor-associated factors (TRAFs) can bind todeveloped calcification of the aorta and renal arteries,
the cytoplasmic domain of RANK as well as to othersuggesting that OPG may also play a role in the control
receptors, like the IL-1 receptor (Arch et al., 1998; Darnayof calcium and phosphate homeostasis (Bucay et al.,
et al., 1999). In osteoclastic precursor cells TRAF6 pref-1998). Although OPG was clearly shown to be a physio-
erentially binds to RANK and leads to the activationlogical regulator of bone resorption, its expression was
of NF-B and the JNK/AP-1 pathway, two importantfound in many tissues other than bone, and its possible
transcription factor complexes involved in osteoclasto-functions in organs such as the heart, kidney, and lung
genesis (see below). When the TRAF6 binding domainare not yet understood.
of RANK was deleted, the truncated receptor was stillIn search for the ligand of OPG expression, cloning
capable of stimulating JNK activity but not NF-B, andidentified the “magic” molecule, the long-sought signal
dominant-negative forms of TRAFs caused inhibition ofthrough which osteoblastic/stromal cells stimulate os-
RANK-mediated NF-B activation (Wong et al., 1998).teoclast formation and resorption, as RANKL (Lacey et
Therefore, TRAFs are required for NF-B activation inal., 1998; Wong et al., 1999; Yasuda et al., 1998). This
RANKL-mediated osteoclast differentiation. The geneticmolecule was identical to a known TNF-related protein,
proof of the role of TRAF6 in osteoclastogenesis stemsTRANCE, and closely related to the apoptosis-inducing
from mouse mutants lacking this protein. These mutantTRAIL/Apo2L protein (Emery et al., 1998). RANKL is pro-
mice developed osteopetrosis with nonfunctional osteo-duced by both preosteoblasts and osteoblasts sur-
clasts (Lomaga et al., 1999; Naito et al., 1999). Severalrounding the cartilaginous anlage, hypertrophic carti-
recent reports including rescue experiments of TRAF6-lage, and cells of trabecular bone, including the
deficient precursors indicate that TRAF6 is involved inosteoclast itself (Kartsogiannis et al., 1999; Lacey et al.,
the differentiation of osteoclasts (Kobayashi et al., 2001).1998; Wong et al., 1997). RANKL administration in mice
Moreover, RANK was shown to activate the anti-apo-leads to increased bone resorption (Burgess et al.,
ptotic Akt/PKB kinase through a signaling complex in-1999), whereas RANKL-deficient mice are osteopetrotic
volving c-Src and TRAF6 (Wong et al., 1999). In theand lack osteoclasts. They also lack lymph nodes and
absence of c-Src, RANKL-dependent Akt activation ishave defects in thymocyte differentiation (Kong et al.,
inhibited, whereas ectopic TRAF6 expression augmented1999). Therefore, RANKL is essential for osteoclast de-
Src-kinase activity. It was known for a long time thatvelopment and T cell differentiation in vivo. Besides its
the absence of c-Src causes osteopetrosis with non-presence as a soluble molecule in the bone microenvi-
functional osteoclasts; the demonstration of a crosstalk
ronment, it is also synthesized by T cells and other
between TRAF6 and c-Src provides an additional level
immune cells (Wong et al., 1997). This provides one
to our understanding of the RANK-dependent regulation
explanation why activation of T cells causes generalized of osteoclast activity (Figure 6). The relevance of the JNK
bone loss and increased osteoclast numbers. In fact, pathway and its associated kinase activity for efficient
increased levels of RANKL are most likely responsible osteoclast differentiation in vitro was recently geneti-
for the observed phenotypes of many immune diseases, cally analyzed in cells from JNK-deficient mice, which
including rheumatoid arthritis (Kong et al., 1999). Impor- have impaired osteoclast differentiation (David and
tantly, together with M-CSF, it is sufficient to induce Wagner, unpublished).
osteoclast differentiation in precursors from spleen or The OPG-RANKL-RANK pathway is therefore of criti-
bone marrow in the absence of any accessory stromal cal importance for osteoclast differentiation. However,
cells in vitro. Are there any RANKL-independent path- it remains to be determined how unique it is and how
ways leading to osteoclasts? At least in vitro, RANKL it controls bone homeostasis beyond development. For
can be replaced by TNF, but whether this is also true instance, it was found that this pathway can be sup-
in vivo is not yet clear. pressed by interferon- produced by T cells through
How does RANKL exert its function? Soluble RANKL rapid degradation of TRAF6, resulting in strong inhibition
binds to its receptor, RANK, which is broadly expressed of JNK and NF-B activation. This established a negative
and was previously found on dendritic cells. RANK is feedback loop between T cell activation and bone re-
also present on chondrocytes and osteoclasts and their sorption (Takayanagi et al., 2000). Very recently, the im-
precursors, (Hsu et al., 1999) and it can be upregulated portance of negative regulation of osteoclastogenesis
was substantiated by demonstrating genetically andby M-CSF (Arai et al., 1999; Lacey et al., 1998). Like OPG,
Review
401
Figure 6. Signaling in Osteoclast Progenitor
Cells and Crosstalk with Interferon Signaling
M-CSF and RANKL are the essential growth
factors, which, following binding to their recep-
tors, trigger a signaling cascade, eventually
leading to the activation of transcription fac-
tors such as c-Fos. This transcription factor
positively controls the generation of osteo-
clasts. However, c-Fos also induces, presum-
ably in the same cell, interferon-, which initi-
ates a negative feedback regulation of RANKL
signaling by suppressing RANKL-induced
c-Fos expression through the induction of in-
terferon-inducible genes.
biochemically that the interferon- pathway also antag- whether c-Fos is needed to maintain the differentiation
state of osteoclasts, although it is likely, since transgeniconizes RANK-dependent signaling. Surprisingly, it was
mice overexpressing c-Fos in osteoclasts using a TRAPfound that interferon- expression is regulated by the
promoter develop remodeling lesions and tumors con-transcription factor c-Fos, which itself is a determinant
taining many osteoclasts (Beedles et al., 1999). Geneti-of osteoclast differentiation (Takayanagi et al., 2000; see
cally, c-Fos can be placed downstream of PU.1 in thealso below).
pathway leading to osteoclast differentiation (Figure 5).The transcription factors acting early in the monocyte/
However, c-Fos not only controls genes positively af-macrophage lineage are those which regulate the devel-
fecting osteoclast differentiation, but it also activatesopment of the bipotential hematopoietic precursor cells
genes like interferon-, which are negatively controllingand the committed precursors destined to become os-
osteoclastogenesis (Takayanagi et al., 2000). Thus, ateoclasts. Only few of them are presently known. How-
unique autoregulatory mechanism is in place whereinever, one of these is PU.1, which encodes an ETS do-
the RANKL-induced c-Fos expression induces its ownmain-containing transcription factor being expressed in
inhibitor, thereby controlling bone homeostasis.the monocytic and B lymphoid lineages. Inactivating the
Some genes acting downstream of c-Fos in the osteo-PU.1 gene in mice demonstrated that PU.1 is essential
clast lineage are known, such as the Fos-related antigenfor lymphoid and myeloid differentiation, since the mu-
fra-1, a bona fide target gene of c-Fos (Matsuo et al.,tant mice are osteopetrotic and lack macrophages as
2000). Gene substitution experiments in mice nicelywell as osteoclasts (McKercher et al., 1996; Tondravi et
demonstrated that Fra-1 can substitute for c-Fos in boneal., 1997). It is worth noting that PU.1 is thought to regu-
development in a gene-dosage-dependent mannerlate the transcription of the M-CSF receptor c-Fms,
(Fleischmann et al., 2000; Matsuo et al., 2000). Moreover,whose downregulation would, at least partly, explain
Fra-1 favors osteoclast differentiation in vitro (Jochumthe osteopetrotic phenotype. Unfortunately, the factors
et al., 2000; Owens et al., 1999), although preliminarycontrolling PU.1 expression are not known, although
data from conditional Fra-1 knockout mice suggest thatthey would be prime candidates to control the early
Fra-1 is not essential for osteoclast formation in vivo anddifferentiation events of the macrophage/osteoclast
in vitro (Schreiber et al., 2000; M. Eferl and E. Wagner,
lineage.
unpublished data). The second Fos-related protein,
Two prominent transcription factor complexes, the Fra-2, which is expressed in the osteoclast lineage (Da-
AP-1 and the NF-B proteins, which are involved in many vid et al., 2001), might be involved in osteoclast differen-
aspects of cell physiology and differentiation, are acti- tiation, since preliminary data from mice lacking Fra-2
vated following growth factor signaling by M-CSF and suggest that they are osteoporotic (M. Eferl and E.
RANKL. Interestingly, individual components of both Wagner, unpublished data).
complexes, which are regulated at multiple levels by Two components of the transcription factor complex
dimerization and phosphorylation, very specifically af- NF-B, the p50 and the p52 subunits, are involved in
fect the osteoclast lineage. Mice without the AP-1 com- osteoclast differentiation. Indeed, the combined dele-
ponent c-Fos lack osteoclasts and are osteopetrotic but tion of these proteins leads to an osteopetrotic pheno-
have an increased number of bone marrow macro- type almost indistinguishable from the c-Fos mutant
phages, a fact which makes it a unique mutation among phenotype and which can also be cured by bone marrow
the many osteopetrotic mice (Grigoriadis et al., 1994). transplantation (Franzoso et al., 1997; Iotsova et al.,
Their osteopetrosis can be rescued by bone marrow 1997). No other NF-B subunits have yet been assigned
transplantation as well as by expression of a c-Fos trans- a specific function in osteoclastogenesis.
gene. These data suggest that c-Fos may play a role in The last transcription factor to be mentioned in this
“instructing” hematopoietic precursors to become os- section is the microphtalmia gene product Mitf (Hodg-
kinson et al., 1993), which was found to be mutated inteoclasts instead of macrophages. It is not yet clear
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